Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab

ARTAÇ, MEHMET; UYSAL, MÜKREMİN; KARAAĞAÇ, MUSTAFA; Korkmaz, Levent; Er, Zehra; Guler, Tunc; Boruban, Melih; Bozcuk, Hakan

doi:10.1007/s12029-016-9879-4

Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab

Atıf İçin Kopyala

ARTAÇ M., UYSAL M., KARAAĞAÇ M., Korkmaz L., Er Z., Guler T., ...Daha Fazla

JOURNAL OF GASTROINTESTINAL CANCER, cilt.48, sa.2, ss.176-180, 2017 (ESCI)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 48 Sayı: 2
Basım Tarihi: 2017
Doi Numarası: 10.1007/s12029-016-9879-4
Dergi Adı: JOURNAL OF GASTROINTESTINAL CANCER
Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
Sayfa Sayıları: ss.176-180
Anahtar Kelimeler: CRP, Neutrophil/lymphocyte ratio, Metastatic colorectal cancer, Bevacizumab, Systemic inflammation, C-REACTIVE PROTEIN, LYMPHOCYTE RATIO, CHEMOTHERAPY, NEUTROPHIL, INDICATOR, CRITERIA
Akdeniz Üniversitesi Adresli: Evet

Özet

Purpose Metastatic colorectal cancer (mCRC) is a lethal disease and fluorouracil-leucovorin-irinotecan (FOLFIRI) plus bevacizumab (bev) is a standard approach. Hence, there is a strong need for identifying new prognostic factors to show the efficacy of FOLFIRI-bev.